UP!

CRL $225.3   View long term graphs

Charles River Laboratories, Inc.
Type
Public
Traded as NYSE: CRL
S&P 400 Component
Industry Pharmaceutical/medical devices
Founded 1947; 70 years ago (1947)
Headquarters Wilmington, Massachusetts
Key people
James C. Foster (CEO)
Revenue $ 1.13 billion (FY2012)
Number of employees
7,500
Website Charles River

Charles River Laboratories, Inc., is an American corporation specializing in a variety of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted biomedical products and research and development outsourcing services for use in the pharmaceutical industry. According to its website, its customers include every major pharmaceutical and biotechnology company in the world, major academic institutions and government research centers.

Charles River was founded in 1947, by a young veterinarian who purchased thousands of rat cages from a Virginia farm and set up a one-man laboratory in Boston, overlooking the Charles River. In an effort to fulfill the regional need for laboratory animal models, he bred, fed and cared for the animals and personally delivered them to local researchers. In the last six decades, this one-man laboratory has evolved into a worldwide network. The organisation is constantly expanding their portfolio, and organisational growth has become a continuous strategic effort in anticipating tomorrow’s drug development needs.

The chairman and chief executive officer is James C. Foster.

In October 2003, Charles River Laboratories merged with Inveresk, a UK-owned research company. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.

In 2010 Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners and Neuberger Berman.

Proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.

In July 2015 the company announced it would acquire Celsis International for $212 million.

In January 2016 the company announced it was set to acquire WIL Research for approximately $585 million in cash.

In June 2016 the company announced it would acquire Blue Stream Laboratories.

The company has been the target of animal rights activists in the UK and US. It owned Shamrock Farm in England's West Sussex which closed in 2000 following a 15-month campaign by animal rights activists.

In 2007, two monkeys at the company’s Sparks, Nevada, facility had their fingers amputated after they were caught in the wiring of their cages while being moved, and a third monkey suffered a cut to its tail.

In 2008, 32 cynomolgus primates, also known as crab-eating macaques, died of overheating at the company's Sparks, Nevada, laboratory after a climate system failure. PETA filed a complaint with the USDA over the incident. The following year, a monkey died at the same facility after being left in their cage as it was going through a hot cage washer. Charles River was fined $14,500 for the two incidents. The company subsequently closed their Sparks facility.

PETA owns $2,000 worth of shares in the company, enough to introduce formal resolutions regarding animal care during the company’s annual shareholder meeting.

News

Charles River Laboratories International, Inc. 2.4% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-02-09 Future report Set alerts
Q3 2020 2020-11-04 Future report Set alerts
Q2 2020 2020-08-05 1.58 1.34
Q1 2020 2020-05-07 1.84 1.02
Q4 2019 2020-02-11 2.01 1.61
Q3 2019 2019-11-06 1.69 1.46
Q2 2019 2019-07-31 1.63 0.88
Q1 2019 2019-05-07 1.40 1.11
Q4 2018 2019-02-13 1.49 1.21
Q3 2018 2018-11-07 1.53 1.22

Ratings

2016-06-20 Initiated Coverage Credit Suisse Neutral $84.00
2016-06-20 Initiated Coverage Credit Suisse Group AG Neutral $84.00
2016-05-22 Reiterated Rating KeyBanc Hold $77.00
2016-05-22 Reiterated Rating KeyCorp Hold $77.00
2016-05-20 Boost Price Target Barclays Underweight $60.00 to $65.00
2016-05-20 Boost Price Target Barclays PLC Underweight $60.00 to $65.00
2016-04-26 Initiated Coverage Gabelli Buy $96.00
2016-02-11 Reiterated Rating Jefferies Buy $96.00 to $90.00
2016-02-11 Reiterated Rating Bank of America Buy $90.00 to $87.00
2016-02-11 Reiterated Rating Jefferies Group Buy $96.00 to $90.00
2016-02-11 Boost Price Target Goldman Sachs Sell $71.00 to $74.00
2016-02-11 Reiterated Rating Deutsche Bank Hold $85.00 to $82.00
2016-02-11 Reiterated Rating Bank of America Corp. Buy $90.00 to $87.00
2016-02-11 Boost Price Target Goldman Sachs Group Inc. Sell $71.00 to $74.00
2016-02-11 Reiterated Rating Deutsche Bank AG Hold $85.00 to $82.00
2016-01-08 Boost Price Target Robert W. Baird Outperform $86.00 to $92.00
2016-01-08 Reiterated Rating Jefferies Group Buy $88.00 to $96.00
2016-01-07 Upgrade Wells Fargo Market Perform to Outperform
2016-01-07 Upgrade Wells Fargo & Co. Market Perform to Outperform
2015-11-05 Boost Price Target Deutsche Bank Hold $79.00 to $81.00
2015-11-02 Boost Price Target Robert W. Baird Outperform $74.00 to $80.00
2015-10-12 Upgrade Wells Fargo Underperform to Market Perform
2015-08-28 Reiterated Rating William Blair Outperform
2015-08-16 Reiterated Rating Jefferies Buy $88.00
2015-08-16 Reiterated Rating Jefferies Group Buy $88.00
2015-08-14 Initiated Coverage Credit Suisse Neutral $84.00
2015-08-13 Reiterated Rating Deutsche Bank Hold $79.00
2015-08-12 Reiterated Rating Jefferies Group Buy $82.00 to $88.00
2015-07-31 Reiterated Rating Citigroup Inc. Hold $75.00 to $77.00
2015-07-31 Boost Price Target Deutsche Bank Hold $76.00 to $79.00
2015-07-10 Reiterated Rating Jefferies Group Buy $82.00
2015-07-10 Reiterated Rating Morgan Stanley Equal Weight $65.00 to $68.00
2015-07-10 Upgrade Bank of America Neutral to Buy $76.00 to $83.00
2015-07-10 Downgrade Barclays Equal Weight to Underweight $60.00
2015-05-28 Reiterated Rating Jefferies Group Buy $82.00
2015-05-04 Upgrade Edward Jones Neutral to Buy
2015-05-04 Upgrade SunTrust Neutral to Buy $88.00
2015-05-04 Upgrade SunTrust Banks Inc. Neutral to Buy $88.00
2015-04-30 Reiterated Rating Cantor Fitzgerald Buy $78.00
2015-04-24 Reiterated Rating Jefferies Group Buy $85.00 to $90.00
2015-04-24 Boost Price Target Barclays Equal Weight $55.00 to $60.00
2015-04-07 Downgrade Wells Fargo & Co. Market Perform to Underperform
2015-04-07 Downgrade Wells Fargo Market Perform to Underperform
2015-03-26 Downgrade SunTrust Buy to Neutral $84.00 to $88.00
2015-02-12 Reiterated Rating Jefferies Group Buy $83.00 to $85.00
2015-02-12 Boost Price Target Deutsche Bank Hold $63.00 to $77.00
2015-02-11 Reiterated Rating Cantor Fitzgerald Buy $70.00
2015-01-28 Reiterated Rating Jefferies Group Buy $80.00 to $83.00
2015-01-23 Upgrade William Blair Market Perform to Outperform
2015-01-16 Boost Price Target Jefferies Group Buy $75.00 to $80.00
2014-11-05 Reiterated Rating Credit Suisse Neutral $60.00 to $67.00
2014-11-03 Reiterated Rating Citigroup Inc. Neutral $56.00 to $65.00
2014-10-31 Reiterated Rating Deutsche Bank Hold $59.00 to $63.00
2014-10-30 Reiterated Rating Jefferies Group Buy $69.00 to $75.00
2014-10-15 Upgrade SunTrust Neutral to Buy $67.00 to $70.00
2014-08-13 Reiterated Rating Deutsche Bank Hold $58.00 to $59.00
2014-08-08 Reiterated Rating Credit Suisse Neutral $56.00 to $60.00
2014-06-24 Initiated Coverage SunTrust Neutral $55.00
2014-05-20 Reiterated Rating Morgan Stanley Equal Weight $60.00
2014-05-06 Lower Price Target Credit Suisse $60.00 to $56.00
2014-05-02 Reiterated Rating Citigroup Inc. Hold $56.00
2014-05-01 Reiterated Rating Jefferies Group Buy
2014-04-30 Initiated Coverage Raymond James Market Perform
2014-04-10 Boost Price Target Jefferies Group Buy $73.00
2014-03-19 Initiated Coverage KeyBanc Hold
2014-02-18 Upgrade Ned Davis Research Neutral to Buy
2014-02-18 Initiated Coverage Citigroup Inc. Sell to Neutral
2014-02-13 Boost Price Target Barclays Equal Weight $41.00 to $55.00
2014-02-13 Boost Price Target Jefferies Group Buy $64.00 to $67.00
2014-01-13 Boost Price Target Sterne Agee CRT $60.00 to $71.00
2014-01-07 Boost Price Target Jefferies Group $57.00 to $64.00
2013-12-11 Upgrade Raymond James Underperform to Market Perform
2013-11-20 Initiated Coverage Deutsche Bank Hold $55.00
2013-11-01 Boost Price Target Sterne Agee CRT Buy $56.00 to $60.00
2013-10-30 Reiterated Rating Credit Suisse Hold $50.00
2013-10-30 Boost Price Target Robert W. Baird Outperform $52.00 to $53.00
2013-10-01 Initiated Coverage Cantor Fitzgerald Buy $53.00
2013-09-23 Initiated Coverage Credit Suisse Neutral $50.00
2013-06-03 Reiterated Barclays Equal Weight $38 to $41
2013-02-14 Reiterated ISI Group Neutral $40.50 to $43
2011-01-06 Downgrade Deutsche Bank Buy to Hold $37 to $37
2010-05-12 Upgrade Robert W. Baird Neutral to Outperform $37
2010-01-07 Upgrade Deutsche Bank Hold to Buy $38.50 to $39
2009-11-09 Downgrade Barclays Capital Overweight to Equal Weight
2009-04-20 Downgrade Jefferies & Co Buy to Hold $33
2009-02-05 Reiterated Barclays Capital Overweight $42 to $38
2009-01-30 Downgrade UBS Neutral to Sell
2009-01-20 Reiterated Barclays Capital Overweight $44 to $42
2008-11-20 Reiterated UBS Neutral $30 to $22
2016-06-20 Initiated Coverage Credit Suisse Neutral $84.00
2016-06-20 Initiated Coverage Credit Suisse Group AG Neutral $84.00
2016-05-22 Reiterated Rating KeyBanc Hold $77.00
2016-05-22 Reiterated Rating KeyCorp Hold $77.00
2016-05-20 Boost Price Target Barclays Underweight $60.00 to $65.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
FOSTER JAMES C Chairman, President and CEO 0.65%  (301676) CRL /
JOHST DAVID P Corp Executive VP 0.42%  (196493) CRL /
ACKERMAN THOMAS F Corp. Executive VP & CFO 0.24%  (111346) CRL / CRY /
REESE C RICHARD 0.12%  (56457) CRL /
CHUBB STEPHEN D 0.07%  (33589) CRL /
MILNE GEORGE M JR 0.06%  (29020) ATHX / CRL / MTD /
GILLETT NANCY Corporate Executive VP 0.06%  (26711) CRL /
BERTOLINI ROBERT J 0.06%  (26195) BMY / CRL /
WALLMAN RICHARD F 0.05%  (24248) CRL / CVG / ROP / STAY / TRNX /
Girshick Birgit Corporate Executive VP 0.05%  (22977) CRL /
Barbo William D Corporate Executive VP & CCO 0.04%  (20980) CRL /
Molho Davide Corporate Executive VP 0.04%  (20669) CRL /
Thompson Craig B. 0.03%  (14929) CRL / MRK /
MASSARO GEORGE 0.03%  (14701) CRL / HURN /
GELLER JORG Corporate Executive VP 0.03%  (14094) CRL /
Smith David Ross Corporate Executive VP & CFO 0.03%  (12778) CRL /
Kochevar Deborah Turner 0.02%  (8786) CRL /
Crowley John J SVP, Chief Accounting Officer 0.01%  (5883) CRL /
MACKAY MARTIN 0.01%  (2782) ALXN / CRL /

Comments